Phenytoin as a novel anti-vitiligo weapon

Journal of Autoimmune Diseases

Volumn 2, Issue , 2005, Pages

  Namazi, M R ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATECHOLAMINE; CYTOKINE; CYTOTOXIN; HYDROGEN PEROXIDE; NORADRENALIN; PHENYTOIN;

ANTICONVULSANT ACTIVITY; ARTICLE; AUTOIMMUNITY; CELL DAMAGE; CELL MEMBRANE PERMEABILITY; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CYTOPLASM; ENZYME ACTIVITY; HELPER CELL; HUMAN; HYPERPIGMENTATION; HYPOTHESIS; MEDICAL RESEARCH; MELANOCYTE; MELANOSOME; NONHUMAN; NORADRENALIN RELEASE; PATHOGENESIS; T LYMPHOCYTE; VITILIGO;

EID: 28844433286     PISSN: 17402557     EISSN: 17402557     Source Type: Journal    
DOI: 10.1186/1740-2557-2-11     Document Type: Article

References (24)

1. Mantovani S, Garbelli S, Palermo B, Campanelli R, Brazzelli V, Borroni G, et al.: Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. J Invest Dermatol 2003, 121:308-14.
2. Namazi MR: Prescribing cyclic antidepressants for vitiligo patients: which agents are superior, which are not? Psychother Psychosom in press.
3. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazzelli V, et al.: Specific cytotoxic T lymphocyte response against Melan-A/MART 1, tyrosinase and GP100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001, 117:326-32.
4. Wankowicz-Kalinska A, van den Wijngaard RM, Tiggers BJ, Westerhof W, Ogg GS, Cerundolo V, et al.: Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest 2003, 83(5):683-95.
5. Mandelcorn-Monson RL, Shear NH, Yau E, Sambhara S, Barber BH, Spaner D, et al.: Cytotoxic T lymphocyte reactivity to gp100, melan A/MART 1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003, 121:550-6.
6. Grimes PE, Ghoneum M, Stockton T, Payne C, Kelly AP, Alfred L: T cell profiles in vitiligo. J Am Acad Dermatol 1986, 14(2 pt 1):196-201.
7. Orecchia GE: Neural pathogenesis. In Vitiligo 1st edition. Edited by: Hann SK, Nordlund JJ. Oxford: Blackwell Scientific Publications; 2000:142-50.
8. Han SK, Chun WH: Autocytotoxic hypothesis for the destruction of melanocytes as the cause of vitiligo. In Vitiligo 1st edition. Edited by: Hann SK, Nordlund JJ. Oxford: Blackwell Scientific Publications; 2000:137-41.
9. Scheinfeld N: Phenytoin in cutaneous medicine: Its uses, mechanisms, and side effects. Dermatol Online J 2003, 9(3):6.
10. Kikuchi K, McCormick CI, Neuwelt EA: Immunosuppression by phenytoin: implication for altered immune competence in brain-tumor patients. J Neurosurg 1984, 61(6):1085-90.
11. Okamoto Y, Shimizu K, Tamura K, Yamada K, Matsui Y, Hayakawa T, et al.: [Effects of anticonvulsants on cellular immunity]. No To Shinkei 1989, 41(3):299-304.
12. Okamoto Y, Shimizu K, Tamura Y, Miyao Y, Yamada M, Tsuda N, et al.: Effects of phenytoin on cell-mediated immunity. Cancer Immunol Immunother 1988, 26(2):176-9.
13. Okamoto Y, Shimizu K, Tamura Y, Miyao Y, Yamada M, Matsui Y, et al.: [Effects of phenytoin on cell-mediated immunity]. No To Shinkei 1987, 39(10):931-6.
14. Okada K, Sugiura T, Kuroda E, Tsuji S, Yamashita U: Phenytoin promotes Th2 type immune response in mice. Clin Exp Immunol 2001, 124:406-13.
15. Chiu HC, Hsieh KH, Hung TP, Young MC: [Humoral and cellmediated immunities in epileptic patients]. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Zazhi 1982, 15(1):30-7.
16. Basaran N, Kansu E, Hincal F: Serum immuno-globulins, complement levels and lymphocyte subpopulations in phenytointreated epileptic patients. Immunopharmacol Immunotoxical 1989, 11(2-3):335-46.
17. Basaran N, Hincal F, Kansu E, Ciger A: Humoral and cellular immune parameters in untreated and phenytoin- or carbamazepine-treated epileptic patients. Int J Immunopharmacol 1994, 16(2):1071-7.
18. Marcoli M, Ricevuti G, Fasani F, Mazzone A, Baiguera R, Tarabini L, et al.: Assessment of lymphocyte and phagocytic cell function in healthy volunteers undergoing short-term phenytoin administration. Int J Immunopharmacol 1987, 9(8):903-12.
19. Grindulis KA, Nichol FE, Oldham R: Phenytoin in rheumatoid arthritis. J Rheumatol 1986, 13(6):1035-9.
20. Porter RJ, Meldrum BS: Antiepileptic drugs. In Basic and Clinical Pharamacology 5th edition. Edited by: Katzung BG. Connecticut: Appleton & Lange; 1992:333-6.
21. Bleehen SS: Disorders of skin color. In Rook/Wilkinson/Ebling Textbook of Dermatology 6th edition. Edited by: Champion RH, Burton JL, Burns DA, Breathnach SM. London: Blackwell Scientific Publications; 1998:1785.
22. Bogaert H, Sanchez E: Lichen planus: Treatment of thirty cases with systemic and topical phenytoin. Int J Dermatol 1990, 29:157-8.
23. Lamoreux L, Boissy RE: Animal models. In Vitiligo 1st edition. Edited by: Hann SK, Nordlund JJ. Oxford: Blackwell Scientific Publications; 2000:281-297.
24. Smyth JR Jr: The Smyth chicken: model of autoimmune amelanosis. Critical Reviews in Poultry Science 1989:1-9.